COX-2 Selective Nonsteroidal Anti-inflammatory Drugs and Risk of Gastrointestinal Tract Complications and Myocardial Infarction An Instrumental Variable Analysis

被引:31
作者
Davies, Neil M. [1 ]
Smith, George Davey [1 ]
Windmeijer, Frank [2 ]
Martin, Richard M. [1 ]
机构
[1] Univ Bristol, MRC, Ctr Causal Anal & Translat Epidemiol, Sch Social & Community Med,Fac Med & Dent, Bristol BS8 2BN, Avon, England
[2] Univ Bristol, Ctr Market & Publ Org, Dept Econ, Fac Social Sci & Law, Bristol BS8 2BN, Avon, England
基金
英国医学研究理事会; 欧洲研究理事会;
关键词
CYCLO-OXYGENASE-2; INHIBITORS; PRESCRIBING PREFERENCE; CAUSAL INFERENCE; ROFECOXIB; DEATH; IDENTIFICATION; EPIDEMIOLOGY; TOXICITY; VALIDITY; DATABASE;
D O I
10.1097/EDE.0b013e318289e024
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: Instrumental variable analysis can estimate treatment effects in the presence of residual or unmeasured confounding. We compared ordinary least squares regression versus instrumental variable estimates of the effects of selective cyclooxygenase-2 inhibitors (COX-2s) relative to nonselective nonsteroidal anti-inflammatory drug (NSAID) prescriptions on incidence of upper gastrointestinal complications and myocardial infarction (MI). Methods: We sampled a cohort of 62,933 first-time users of COX-2s or nonselective NSAIDs older than 60 years in the Clinical Practice Research Datalink. The instruments were physicians' previous prescriptions of COX-2s or nonselective NSAIDs, which are surrogates for physician preferences. We estimated risk differences of incident upper gastrointestinal complications and MI within 180 days of first COX-2 versus nonselective NSAID prescription. Results: Using ordinary least squares regression, adjusted for baseline confounders, we observed little association of COX-2 prescriptions with incident upper gastrointestinal complications (risk difference = -0.08 [95% confidence interval = -0.20 to 0.04]) or MI (0.06 [-0.06 to 0.17]) per 100 patients treated. Our adjusted instrumental variable results suggested 0.46 per 100 (-0.15 to 1.07) fewer upper gastrointestinal complications and little difference in acute MIs (0.08 per 100 [-0.61 to 0.76]), within 180 days of being prescribed COX-2s. Estimates were more precise when we used 20 previous prescriptions; the instrumental variable analysis implied 0.74 (0.28 to 1.19) fewer MIs per 100 patients prescribed COX-2s. Conclusions: Using instrumental variable analysis, we found some evidence that COX-2 prescriptions reduced the risk of upper gastrointestinal complications, consistent with randomized controlled trials. Our results using multiple instruments suggest that COX-2s may have heterogeneous within-class effects on MI. (Epidemiology 2013;24:352-362)
引用
收藏
页码:352 / 362
页数:11
相关论文
共 65 条
[1]   Reducing the Variance of the Prescribing Preference-based Instrumental Variable Estimates of the Treatment Effect [J].
Abrahamowicz, Michal ;
Beauchamp, Marie-Eve ;
Ionescu-Ittu, Raluca ;
Delaney, Joseph A. C. ;
Pilote, Louise .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 174 (04) :494-502
[2]   Using Maimonides' rule to estimate the effect of class size on scholastic achievement [J].
Angrist, JD ;
Lavy, V .
QUARTERLY JOURNAL OF ECONOMICS, 1999, 114 (02) :533-575
[3]  
Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629
[4]   2-STAGE LEAST-SQUARES ESTIMATION OF AVERAGE CAUSAL EFFECTS IN MODELS WITH VARIABLE TREATMENT INTENSITY [J].
ANGRIST, JD ;
IMBENS, GW .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1995, 90 (430) :431-442
[5]   Estimation of limited dependent variable models with dummy endogenous regressors: Simple strategies for empirical practice [J].
Angrist, JD .
JOURNAL OF BUSINESS & ECONOMIC STATISTICS, 2001, 19 (01) :2-16
[6]  
[Anonymous], 2010, GPRD DATABASE
[7]  
[Anonymous], 2011, Stata statistical software: Release 12
[8]   Bounds on treatment effects from studies with imperfect compliance [J].
Balke, A ;
Pearl, J .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1997, 92 (439) :1171-1176
[9]  
Baum C. F., 2007, IVREG2 STATA MODULE
[10]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528